Global Atopic Dermatitis Drugs research

Atopic Dermatitis Drugs Comprehensive Study by Type (Topical, Injectable, Oral), Application (Hospital, Clinic, Home care.), Distribution Channel (Hospital Pharmacies , Retail Pharmacies , Online Pharmacies, Others), Class Type (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others) Players and Region - Global Market Outlook to 2027

Atopic Dermatitis Drugs Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 5.98%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Atopic Dermatitis Drugs Market Scope
Atopic dermatitis drugs is used to treat atopic dermatitis disease. Atopic dermatitis is a widespread chronic inflammatory skin diseases that can affect patients of all ages of people. Recent developments by numerous key players have reignited interest in the treatment of the diseases. For instance, Upcoming patent expiration of key products, such as LEO Pharma’s Protopic, Mylan/Valeant’s Elidel, and Bayer’s Desonate will result in generic penetration in therapeutic space.

According to AMA, the Global Atopic Dermatitis Drugs market is expected to see growth rate of 5.98%

Encore Dermatology, Inc. (United States), Mylan (United States), Valeant (Canada), Bayer HealthCare (Germany), LEO Pharma (Denmark), Pfizer (United States), Sanofi (France), GlaxoSmithKline plc. (United Kingdom), Bausch Health (Canada) and F. Hoffmann-La Roche Ltd (Switzerland) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Atopic Dermatitis Drugs market by Type (Topical, Injectable and Oral), by Application (Hospital, Clinic and Home care.) and Region with country level break-up.

On the basis of geography, the market of Atopic Dermatitis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In September 2018, LEO Pharma declare its agreement with JW Pharmaceutical (JWP), where LEO Pharma will get rights to modify, develop and commercialize JW1601, which is anovel atopic dermatitis drug candidate intended for oral treatment of atopic dermatitis.


Market Trend
  • Increasing Acceptance of Targeted Therapies such as Eucrisa and Dupixent

Market Drivers
  • Increasing Awareness Regarding the Availability of Treatments for the Disease Worldwide
  • Various Countries Government Initiatives to Offer Better and More Affordable Treatment

Opportunities
  • The Rising Favorable Reimbursement Policies by Government Specifically in Emerging Economies

Restraints
  • Allergic Reactions of off-label Therapies
  • High Cost of Therapeutics

Challenges
  • Strict government regulations and legal norms


Report Objectives / Segmentation Covered

By Type
  • Topical
  • Injectable
  • Oral
By Application
  • Hospital
  • Clinic
  • Home care.
By Distribution Channel
  • Hospital Pharmacies 
  • Retail Pharmacies 
  • Online Pharmacies
  • Others

By Class Type
  • Corticosteroids
  • Calcineurin Inhibitors
  • PDE4 Inhibitors
  • Biologics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness Regarding the Availability of Treatments for the Disease Worldwide
      • 3.2.2. Various Countries Government Initiatives to Offer Better and More Affordable Treatment
    • 3.3. Market Challenges
      • 3.3.1. Strict government regulations and legal norms
    • 3.4. Market Trends
      • 3.4.1. Increasing Acceptance of Targeted Therapies such as Eucrisa and Dupixent
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Atopic Dermatitis Drugs, by Type, Application, Distribution Channel, Class Type and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Atopic Dermatitis Drugs (Value)
      • 5.2.1. Global Atopic Dermatitis Drugs by: Type (Value)
        • 5.2.1.1. Topical
        • 5.2.1.2. Injectable
        • 5.2.1.3. Oral
      • 5.2.2. Global Atopic Dermatitis Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Home care.
      • 5.2.3. Global Atopic Dermatitis Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies 
        • 5.2.3.2. Retail Pharmacies 
        • 5.2.3.3. Online Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Atopic Dermatitis Drugs by: Class Type (Value)
        • 5.2.4.1. Corticosteroids
        • 5.2.4.2. Calcineurin Inhibitors
        • 5.2.4.3. PDE4 Inhibitors
        • 5.2.4.4. Biologics
        • 5.2.4.5. Others
      • 5.2.5. Global Atopic Dermatitis Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Atopic Dermatitis Drugs (Price)
      • 5.3.1. Global Atopic Dermatitis Drugs by: Type (Price)
  • 6. Atopic Dermatitis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Encore Dermatology, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mylan (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Valeant (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer HealthCare (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. LEO Pharma (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bausch Health (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Atopic Dermatitis Drugs Sale, by Type, Application, Distribution Channel, Class Type and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Atopic Dermatitis Drugs (Value)
      • 7.2.1. Global Atopic Dermatitis Drugs by: Type (Value)
        • 7.2.1.1. Topical
        • 7.2.1.2. Injectable
        • 7.2.1.3. Oral
      • 7.2.2. Global Atopic Dermatitis Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Home care.
      • 7.2.3. Global Atopic Dermatitis Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies 
        • 7.2.3.2. Retail Pharmacies 
        • 7.2.3.3. Online Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Atopic Dermatitis Drugs by: Class Type (Value)
        • 7.2.4.1. Corticosteroids
        • 7.2.4.2. Calcineurin Inhibitors
        • 7.2.4.3. PDE4 Inhibitors
        • 7.2.4.4. Biologics
        • 7.2.4.5. Others
      • 7.2.5. Global Atopic Dermatitis Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Atopic Dermatitis Drugs (Price)
      • 7.3.1. Global Atopic Dermatitis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Atopic Dermatitis Drugs: by Type(USD Million)
  • Table 2. Atopic Dermatitis Drugs Topical , by Region USD Million (2016-2021)
  • Table 3. Atopic Dermatitis Drugs Injectable , by Region USD Million (2016-2021)
  • Table 4. Atopic Dermatitis Drugs Oral , by Region USD Million (2016-2021)
  • Table 5. Atopic Dermatitis Drugs: by Application(USD Million)
  • Table 6. Atopic Dermatitis Drugs Hospital , by Region USD Million (2016-2021)
  • Table 7. Atopic Dermatitis Drugs Clinic , by Region USD Million (2016-2021)
  • Table 8. Atopic Dermatitis Drugs Home care. , by Region USD Million (2016-2021)
  • Table 9. Atopic Dermatitis Drugs: by Distribution Channel(USD Million)
  • Table 10. Atopic Dermatitis Drugs Hospital Pharmacies  , by Region USD Million (2016-2021)
  • Table 11. Atopic Dermatitis Drugs Retail Pharmacies  , by Region USD Million (2016-2021)
  • Table 12. Atopic Dermatitis Drugs Online Pharmacies , by Region USD Million (2016-2021)
  • Table 13. Atopic Dermatitis Drugs Others , by Region USD Million (2016-2021)
  • Table 14. Atopic Dermatitis Drugs: by Class Type(USD Million)
  • Table 15. Atopic Dermatitis Drugs Corticosteroids , by Region USD Million (2016-2021)
  • Table 16. Atopic Dermatitis Drugs Calcineurin Inhibitors , by Region USD Million (2016-2021)
  • Table 17. Atopic Dermatitis Drugs PDE4 Inhibitors , by Region USD Million (2016-2021)
  • Table 18. Atopic Dermatitis Drugs Biologics , by Region USD Million (2016-2021)
  • Table 19. Atopic Dermatitis Drugs Others , by Region USD Million (2016-2021)
  • Table 20. South America Atopic Dermatitis Drugs, by Country USD Million (2016-2021)
  • Table 21. South America Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 22. South America Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 23. South America Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 24. South America Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 25. Brazil Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 26. Brazil Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 27. Brazil Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 28. Brazil Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 29. Argentina Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 30. Argentina Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 31. Argentina Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 32. Argentina Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 33. Rest of South America Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 35. Rest of South America Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 36. Rest of South America Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 37. Asia Pacific Atopic Dermatitis Drugs, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 40. Asia Pacific Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 41. Asia Pacific Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 42. China Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 43. China Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 44. China Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 45. China Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 46. Japan Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 47. Japan Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 48. Japan Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 49. Japan Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 50. India Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 51. India Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 52. India Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 53. India Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 54. South Korea Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 55. South Korea Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 56. South Korea Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 57. South Korea Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 58. Taiwan Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 59. Taiwan Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 60. Taiwan Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 61. Taiwan Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 62. Australia Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 63. Australia Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 64. Australia Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 65. Australia Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 70. Europe Atopic Dermatitis Drugs, by Country USD Million (2016-2021)
  • Table 71. Europe Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 72. Europe Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 73. Europe Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 74. Europe Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 75. Germany Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 76. Germany Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 77. Germany Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 78. Germany Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 79. France Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 80. France Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 81. France Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 82. France Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 83. Italy Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 84. Italy Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 85. Italy Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 86. Italy Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 87. United Kingdom Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 88. United Kingdom Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 89. United Kingdom Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 90. United Kingdom Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 91. Netherlands Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 92. Netherlands Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 93. Netherlands Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 94. Netherlands Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 95. Rest of Europe Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 96. Rest of Europe Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 97. Rest of Europe Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 98. Rest of Europe Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 99. MEA Atopic Dermatitis Drugs, by Country USD Million (2016-2021)
  • Table 100. MEA Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 101. MEA Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 102. MEA Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 103. MEA Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 104. Middle East Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 105. Middle East Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 106. Middle East Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 107. Middle East Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 108. Africa Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 109. Africa Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 110. Africa Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 111. Africa Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 112. North America Atopic Dermatitis Drugs, by Country USD Million (2016-2021)
  • Table 113. North America Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 114. North America Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 115. North America Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 116. North America Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 117. United States Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 118. United States Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 119. United States Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 120. United States Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 121. Canada Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 122. Canada Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 123. Canada Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 124. Canada Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 125. Mexico Atopic Dermatitis Drugs, by Type USD Million (2016-2021)
  • Table 126. Mexico Atopic Dermatitis Drugs, by Application USD Million (2016-2021)
  • Table 127. Mexico Atopic Dermatitis Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 128. Mexico Atopic Dermatitis Drugs, by Class Type USD Million (2016-2021)
  • Table 129. Atopic Dermatitis Drugs: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Atopic Dermatitis Drugs: by Type(USD Million)
  • Table 141. Atopic Dermatitis Drugs Topical , by Region USD Million (2022-2027)
  • Table 142. Atopic Dermatitis Drugs Injectable , by Region USD Million (2022-2027)
  • Table 143. Atopic Dermatitis Drugs Oral , by Region USD Million (2022-2027)
  • Table 144. Atopic Dermatitis Drugs: by Application(USD Million)
  • Table 145. Atopic Dermatitis Drugs Hospital , by Region USD Million (2022-2027)
  • Table 146. Atopic Dermatitis Drugs Clinic , by Region USD Million (2022-2027)
  • Table 147. Atopic Dermatitis Drugs Home care. , by Region USD Million (2022-2027)
  • Table 148. Atopic Dermatitis Drugs: by Distribution Channel(USD Million)
  • Table 149. Atopic Dermatitis Drugs Hospital Pharmacies  , by Region USD Million (2022-2027)
  • Table 150. Atopic Dermatitis Drugs Retail Pharmacies  , by Region USD Million (2022-2027)
  • Table 151. Atopic Dermatitis Drugs Online Pharmacies , by Region USD Million (2022-2027)
  • Table 152. Atopic Dermatitis Drugs Others , by Region USD Million (2022-2027)
  • Table 153. Atopic Dermatitis Drugs: by Class Type(USD Million)
  • Table 154. Atopic Dermatitis Drugs Corticosteroids , by Region USD Million (2022-2027)
  • Table 155. Atopic Dermatitis Drugs Calcineurin Inhibitors , by Region USD Million (2022-2027)
  • Table 156. Atopic Dermatitis Drugs PDE4 Inhibitors , by Region USD Million (2022-2027)
  • Table 157. Atopic Dermatitis Drugs Biologics , by Region USD Million (2022-2027)
  • Table 158. Atopic Dermatitis Drugs Others , by Region USD Million (2022-2027)
  • Table 159. South America Atopic Dermatitis Drugs, by Country USD Million (2022-2027)
  • Table 160. South America Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 161. South America Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 162. South America Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 163. South America Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 164. Brazil Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 165. Brazil Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 166. Brazil Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 167. Brazil Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 168. Argentina Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 169. Argentina Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 170. Argentina Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 171. Argentina Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 172. Rest of South America Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 173. Rest of South America Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 174. Rest of South America Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 175. Rest of South America Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 176. Asia Pacific Atopic Dermatitis Drugs, by Country USD Million (2022-2027)
  • Table 177. Asia Pacific Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 178. Asia Pacific Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 179. Asia Pacific Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 180. Asia Pacific Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 181. China Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 182. China Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 183. China Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 184. China Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 185. Japan Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 186. Japan Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 187. Japan Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 188. Japan Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 189. India Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 190. India Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 191. India Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 192. India Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 193. South Korea Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 194. South Korea Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 195. South Korea Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 196. South Korea Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 197. Taiwan Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 198. Taiwan Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 199. Taiwan Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 200. Taiwan Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 201. Australia Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 202. Australia Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 203. Australia Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 204. Australia Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 205. Rest of Asia-Pacific Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 206. Rest of Asia-Pacific Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 207. Rest of Asia-Pacific Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 209. Europe Atopic Dermatitis Drugs, by Country USD Million (2022-2027)
  • Table 210. Europe Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 211. Europe Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 212. Europe Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 213. Europe Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 214. Germany Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 215. Germany Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 216. Germany Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 217. Germany Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 218. France Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 219. France Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 220. France Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 221. France Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 222. Italy Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 223. Italy Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 224. Italy Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 225. Italy Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 226. United Kingdom Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 227. United Kingdom Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 228. United Kingdom Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 229. United Kingdom Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 230. Netherlands Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 231. Netherlands Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 232. Netherlands Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 233. Netherlands Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 234. Rest of Europe Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 235. Rest of Europe Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 236. Rest of Europe Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 237. Rest of Europe Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 238. MEA Atopic Dermatitis Drugs, by Country USD Million (2022-2027)
  • Table 239. MEA Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 240. MEA Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 241. MEA Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 242. MEA Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 243. Middle East Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 244. Middle East Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 245. Middle East Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 246. Middle East Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 247. Africa Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 248. Africa Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 249. Africa Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 250. Africa Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 251. North America Atopic Dermatitis Drugs, by Country USD Million (2022-2027)
  • Table 252. North America Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 253. North America Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 254. North America Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 255. North America Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 256. United States Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 257. United States Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 258. United States Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 259. United States Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 260. Canada Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 261. Canada Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 262. Canada Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 263. Canada Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 264. Mexico Atopic Dermatitis Drugs, by Type USD Million (2022-2027)
  • Table 265. Mexico Atopic Dermatitis Drugs, by Application USD Million (2022-2027)
  • Table 266. Mexico Atopic Dermatitis Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 267. Mexico Atopic Dermatitis Drugs, by Class Type USD Million (2022-2027)
  • Table 268. Atopic Dermatitis Drugs: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Atopic Dermatitis Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Atopic Dermatitis Drugs: by Application USD Million (2016-2021)
  • Figure 6. Global Atopic Dermatitis Drugs: by Distribution Channel USD Million (2016-2021)
  • Figure 7. Global Atopic Dermatitis Drugs: by Class Type USD Million (2016-2021)
  • Figure 8. South America Atopic Dermatitis Drugs Share (%), by Country
  • Figure 9. Asia Pacific Atopic Dermatitis Drugs Share (%), by Country
  • Figure 10. Europe Atopic Dermatitis Drugs Share (%), by Country
  • Figure 11. MEA Atopic Dermatitis Drugs Share (%), by Country
  • Figure 12. North America Atopic Dermatitis Drugs Share (%), by Country
  • Figure 13. Global Atopic Dermatitis Drugs: by Type USD/Units (2016-2021)
  • Figure 14. Global Atopic Dermatitis Drugs share by Players 2021 (%)
  • Figure 15. Global Atopic Dermatitis Drugs share by Players (Top 3) 2021(%)
  • Figure 16. Global Atopic Dermatitis Drugs share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Encore Dermatology, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Encore Dermatology, Inc. (United States) Revenue: by Geography 2021
  • Figure 20. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 21. Mylan (United States) Revenue: by Geography 2021
  • Figure 22. Valeant (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Valeant (Canada) Revenue: by Geography 2021
  • Figure 24. Bayer HealthCare (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer HealthCare (Germany) Revenue: by Geography 2021
  • Figure 26. LEO Pharma (Denmark) Revenue, Net Income and Gross profit
  • Figure 27. LEO Pharma (Denmark) Revenue: by Geography 2021
  • Figure 28. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer (United States) Revenue: by Geography 2021
  • Figure 30. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi (France) Revenue: by Geography 2021
  • Figure 32. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 34. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Bausch Health (Canada) Revenue: by Geography 2021
  • Figure 36. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 38. Global Atopic Dermatitis Drugs: by Type USD Million (2022-2027)
  • Figure 39. Global Atopic Dermatitis Drugs: by Application USD Million (2022-2027)
  • Figure 40. Global Atopic Dermatitis Drugs: by Distribution Channel USD Million (2022-2027)
  • Figure 41. Global Atopic Dermatitis Drugs: by Class Type USD Million (2022-2027)
  • Figure 42. South America Atopic Dermatitis Drugs Share (%), by Country
  • Figure 43. Asia Pacific Atopic Dermatitis Drugs Share (%), by Country
  • Figure 44. Europe Atopic Dermatitis Drugs Share (%), by Country
  • Figure 45. MEA Atopic Dermatitis Drugs Share (%), by Country
  • Figure 46. North America Atopic Dermatitis Drugs Share (%), by Country
  • Figure 47. Global Atopic Dermatitis Drugs: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Encore Dermatology, Inc. (United States)
  • Mylan (United States)
  • Valeant (Canada)
  • Bayer HealthCare (Germany)
  • LEO Pharma (Denmark)
  • Pfizer (United States)
  • Sanofi (France)
  • GlaxoSmithKline plc. (United Kingdom)
  • Bausch Health (Canada)
  • F. Hoffmann-La Roche Ltd (Switzerland)
Select User Access Type

Key Highlights of Report


Mar 2022 228 Pages 50 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Atopic Dermatitis Drugs research Quantitative research analysis
Global Atopic Dermatitis Drugs research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Atopic Dermatitis Drugs study can be customized to meet your requirements. The market size breakdown by type [Topical, Injectable and Oral], by end use application [Hospital, Clinic and Home care.].
The Atopic Dermatitis Drugs Market is gaining popularity and expected to see strong valuation by 2027.
According to AMA, the Global Atopic Dermatitis Drugs market is expected to see growth rate of 5.98%.

Know More About Global Atopic Dermatitis Drugs research Report?

Have a Query? Click Here

Other Related Reports

Health and Wellness Comprehensive Study by Type (Health and Wellness Food (Functional food, Naturally health food, Better-for-you (BFY) food, Food intolerance products, Organic food), Health and Well...
$ 3750
Antiepileptic Drugs Comprehensive Study by Drug (First Generation, Second Generation, Pipeline Drugs), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail P...
$ 3450
Prenatal Vitamin Supplements Comprehensive Study by Type (Folic Acid, Calcium, Iron, Vitamin D, Others), Distribution Channels (Retail Stores, Direct Selling, Online Stores), Dosage Forms (Capsule, P...
$ 3500
Ayurvedic Medicine Comprehensive Study by Type (Healthcare Products, Personal Care Products, Skin Care, Hair Care, Oral Care, Others), Application (Skin Diseases, Cardiovascular, Diabetes, Autoimmune...
$ 3750
Vitamin K1 Comprehensive Study by Type (Food Grade, Feed Grade, Pharmaceutical Grade, Others), Application (Functional Food & Beverages, Dietary Supplements, Pharmaceuticals, Others) Players and Regi...
$ 3500
Live Attenuated Vaccines Comprehensive Study by Type (Bacterial, Viral), Application (Hospitals, Clinics, Research Institutes, Others), (), End Use (Geriatrics, Adults, Adolescents, Child), Vaccines...
$ 3450